Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 18
Symposium

127 - Pathogen-specific clinical trials: promise and practical considerations

Saturday, October 2, 2021
10:00 AM - 11:15 AM EDT

    Moderator(s)

  • Yohei Doi, MD, PHD

    Professor of Medicine
    Division of Infectious Diseases
    University of Pittsburgh
    Pittsburgh, PA, United States

    Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant

    • Speaker(s)

  • Thomas Lodise, Jr., PharmD, PhD

    Professor, Pharmacy Practice
    Albany College of Pharmacy and Health Sciences
    Albany, New York, United States

    Melinta Therapeutics (Individual(s) Involved: Self): Consultant; Merck (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Paratek (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant, Speakers' bureau; Spero (Individual(s) Involved: Self): Consultant; Tetraphase Pharmaceuticals Inc. (Individual(s) Involved: Self): Consultant

  • Asha Bowen, BA, MBBS, DCH, FRACP, PhD

    Head of Department of Infectious Diseases
    Perth Children's Hospital
    Nedlands, Australia

    NHMRC (Individual(s) Involved: Self): Competitive Funding for SNAP Trial, Grant/Research Support, Other Financial or Material Support

Participants should be aware of the following financial/non-financial relationships:
Yohei Doi, MD, PhD: Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant
Thomas Lodise, Jr., PharmD, PhD: Melinta Therapeutics (Individual(s) Involved: Self): Consultant; Merck (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Paratek (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant, Speakers' bureau; Spero (Individual(s) Involved: Self): Consultant; Tetraphase Pharmaceuticals Inc. (Individual(s) Involved: Self): Consultant
Asha C. Bowen, BA, MBBS, DCH, FRACP, PhD: NHMRC (Individual(s) Involved: Self): Competitive Funding for SNAP Trial, Grant/Research Support, Other Financial or Material Support

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • describe the potential value of pathogen-specific clinical trials
  • discuss the complexities and challenges of such trials
  • interpret trial data for application in clinical practice

Presentations:

  • Gram-negative Trials: Lessons Learned

    Speaker: Thomas Lodise, Jr., PharmD, PhD – Albany College of Pharmacy and Health Sciences

  • The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial

    Speaker: Asha C. Bowen, BA, MBBS, DCH, FRACP, PhD – Perth Children's Hospital